How to Choose an Expression System for Recombinant Nanobodies

For most recombinant nanobodies intended for research or veterinary diagnostic development, I would evaluate Escherichia coli first because it is widely used for producing small antibody fragments and can support a straightforward, economical workflow. I would choose yeast when secretion or scalable eukaryotic production is a priority, and mammalian cells when the construct or intended use requires mammalian-specific processing. The right choice depends on the nanobody sequence, folding and solubility, required modifications, application, and acceptable development cost—not on a single system being best for every project.

You can find more information on our web, so please take a look.

A nanobody, often called a VHH antibody fragment, is a single-domain binding protein derived from camelid heavy-chain antibodies or designed from related sequences. Its compact structure is commonly around 15 kDa, although the exact mass varies with the sequence and any attached tags or fusion partners. Below, I explain how I compare expression options and what information I recommend preparing before requesting a recombinant nanobody expression service.

Key Takeaways

• Start with the application: research assays, veterinary diagnostics, and therapeutic development can have different requirements for purity, activity, and characterization.
• Use E. coli as an initial candidate, not an automatic answer: compare soluble yield and functional binding with the alternatives.
• Consider secretion and processing: yeast or mammalian expression may be useful when the construct benefits from eukaryotic production or secretion.
• Define acceptance criteria early: agree on the intended construct, purification, quality checks, and deliverables before production begins.

Start with the Intended Use and Product Requirements

Before selecting a host, I define what the nanobody must do after production. A reagent for exploratory binding studies may have different requirements from a diagnostic capture reagent intended for a veterinary assay, while a candidate for therapeutic research calls for a more demanding development and characterization plan. The expression system should be selected against measurable project needs rather than general claims about yield or convenience.

Questions to answer before choosing a host

• Will the protein be used in an ELISA, immunoassay, imaging assay, functional experiment, or another application?
• Does the construct include a purification or detection tag, a linker, or a fusion partner?
• Is secretion into the culture medium important, or is intracellular production acceptable?
• What purity, quantity, activity, and analytical documentation are needed for the next project stage?
• Does the sequence contain features that may affect folding, solubility, or post-translational processing?

Compare the Main Expression Systems

Each expression platform brings trade-offs in development effort, production format, protein processing, and downstream purification. A sequence that expresses well in one host may perform differently in another, so a small comparative screen can be more informative than selecting a platform based on species or application alone. The table is a starting point; actual outcomes depend on the construct and process conditions.

A Practical Selection Framework

1. Review the sequence and construct design

Share the complete amino acid sequence and clarify whether the project includes a signal peptide, affinity tag, linker, or fusion partner. Ask the provider to check for sequence features that could complicate expression or purification, while treating such predictions as hypotheses to test rather than guarantees. If more than one construct format is possible, compare the simplest functional design with any format required for the assay.

2. Match the host to folding and processing needs

Many nanobodies can be produced in bacterial systems, but the host does not remove the need to verify correct folding and binding. If soluble expression is poor, a project team may evaluate different construct designs, expression conditions, or an alternative host. Yeast and mammalian cells are worth considering when secretion or eukaryotic processing is relevant, but their use should be justified by product requirements rather than assumed to improve performance.

3. Screen before committing to scale

When the best host is uncertain, I recommend a staged plan: small-scale expression, analysis of soluble and insoluble fractions where applicable, purification of promising material, and a binding or functional assay suited to the intended use. For example, 37°C is a commonly used reference temperature for bacterial growth, but it is not a universal optimum for nanobody expression. Lower-temperature conditions such as 20–30°C may be included in a screening design when slower production could help evaluate soluble expression; results must be confirmed experimentally for the specific construct.

4. Define analytical and functional acceptance criteria

Protein concentration and apparent size are useful, but they do not establish that a nanobody retains target binding. Discuss which checks are appropriate, such as purity assessment, identity confirmation, concentration measurement, and an application-relevant binding assay. For veterinary diagnostic development, also consider whether the sample matrix, assay format, and target species are represented in later validation work; production alone does not establish diagnostic performance.

If you want to learn more, please visit our website NBbiolab.

Common Selection Mistakes

• Choosing only by quoted yield: total protein output is not the same as purified, correctly folded, active nanobody.
• Assuming one host fits every sequence: sequence context, tags, and intended use can change the best production route.
• Overlooking endotoxin requirements: this may matter for certain cell-based or animal-related research workflows, so clarify it before production.
• Ignoring glycosylation or other processing: eukaryotic expression can introduce processing differences that should be considered for the assay.
• Ordering scale before confirming activity: a small feasibility stage can reduce the risk of scaling a construct that does not meet functional needs.

Supplier Evaluation and Project Planning

When comparing recombinant nanobody suppliers, I look for a clear explanation of the proposed host, construct assumptions, purification plan, and project decision points. Ask whether the service includes sequence review, expression screening, scale-up, purification, and analytical reporting, because these items may be offered as separate stages. Also confirm the expected sample format, quantity range, storage and shipping conditions, and how deviations from the agreed acceptance criteria will be discussed.

Price, minimum order quantity, and lead time depend on the sequence, host, scale, purification requirements, and requested testing. Rather than relying on a generic estimate, provide the sequence and project scope so the supplier can distinguish feasibility work from production. A staged quote can make the trade-off clearer: first evaluate expression and activity, then proceed to a larger batch only if the candidate meets the agreed criteria.

Recommendations by Project Scenario

Research reagent or early assay development

Begin by evaluating an E. coli workflow if the sequence and construct are compatible, and include a functional binding check before ordering a larger amount. If soluble recovery or activity is inadequate, discuss construct or host alternatives with the supplier. For assay development, make sure the purified format and tag are compatible with the planned detection method.

Veterinary diagnostic development

Prioritize reproducible binding in the intended assay format and assess performance using relevant veterinary samples or matrices during the appropriate validation stage. Ask for a consistent construct and documented production specifications if repeat batches will be needed. A successful expression result is a production milestone, not proof that a diagnostic assay is validated for clinical use.

More complex or therapeutic research constructs

For constructs with fusion partners or a defined need for eukaryotic processing, compare yeast or mammalian options with microbial production. Consider whether modifications could affect binding, stability, or downstream interpretation. The expression choice should be reviewed alongside the broader development and regulatory plan rather than treated as a substitute for it.

Conclusion: Choose by Evidence from Your Construct

For many recombinant nanobody projects, E. coli is a sensible first system to evaluate, while yeast, mammalian, or cell-free expression may be better suited to specific processing, secretion, or screening needs. I recommend deciding through sequence review, small-scale comparison, purification assessment, and a functional assay tied to the intended veterinary or research application. This approach helps balance performance, timeline, and cost without assuming that any host is universally optimal.

To plan a project with NBbiolab, prepare the nanobody sequence, intended application, desired quantity, construct or tag preferences, and any required analytical checks. Our team can use these details to discuss a suitable expression route and a practical scope for recombinant nanobody expression and purification. Contact NBbiolab to request a project assessment and quotation.